AllianceBernstein
IMVT icon

AllianceBernstein’s Immunovant IMVT Stock Holding History

AllianceBernstein’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.9M Buy
116,860
+26,450
+29% +$806K ﹤0.01% 1835
2026
Q1 		$2.3M Buy
90,410
+1,250
+1% +$32.4K ﹤0.01% 1918
2025
Q4 		$2.27M Sell
89,160
-463
-0.5% -$10.3K ﹤0.01% 1927
2025
Q3 		$1.44M Buy
89,623
+5,663
+7% +$91.7K ﹤0.01% 2170
2025
Q2 		$1.34M Buy
83,960
+9,110
+12% +$138K ﹤0.01% 2131
2025
Q1 		$1.28M Hold
74,850
– – ﹤0.01% 2118
2024
Q4 		$1.85M Buy
74,850
+4,200
+6% +$119K ﹤0.01% 1997
2024
Q3 		$2.01M Sell
70,650
-800
-1% -$23.6K ﹤0.01% 1968
2024
Q2 		$1.89M Buy
71,450
+4,300
+6% +$122K ﹤0.01% 1991
2024
Q1 		$2.17M Sell
67,150
-5,710
-8% -$208K ﹤0.01% 1878
2023
Q4 		$3.07M Sell
72,860
-1,600
-2% -$58.9K ﹤0.01% 1715
2023
Q3 		$2.86M Buy
74,460
+5,760
+8% +$130K ﹤0.01% 1691
2023
Q2 		$1.3M Buy
68,700
+11,400
+20% +$213K ﹤0.01% 2137
2023
Q1 		$889K Sell
57,300
-23,400
-29% -$406K ﹤0.01% 2292
2022
Q4 		$1.43M Sell
80,700
-5,300
-6% -$66.7K ﹤0.01% 2096
2022
Q3 		$480K Buy
86,000
+2,400
+3% +$11.7K ﹤0.01% 2666
2022
Q2 		$326K Buy
83,600
+3,500
+4% +$15.1K ﹤0.01% 2845
2022
Q1 		$441K Buy
80,100
+200
+0.3% +$1.25K ﹤0.01% 2733
2021
Q4 		$681K Sell
79,900
-4,600
-5% -$38K ﹤0.01% 2617
2021
Q3 		$734K Sell
84,500
-8,000
-9% -$72.2K ﹤0.01% 2616
2021
Q2 		$978K Buy
92,500
+59,000
+176% +$824K ﹤0.01% 2542
2021
Q1 		$537K Sell
33,500
-43,937
-57% -$1.16M ﹤0.01% 2632
2020
Q4 		$3.58M Sell
77,437
-97,978
-56% -$4.53M ﹤0.01% 1684
2020
Q3 		$6.17M Buy
175,415
+66,756
+61% +$2.01M ﹤0.01% 1239
2020
Q2 		$2.65M Buy
108,659
+53,505
+97% +$1.15M ﹤0.01% 1687
2020
Q1 		$858K Buy
+55,154
New +$830K ﹤0.01% 2095

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AllianceBernstein's IMVT Position: Q2 2026 in Review

AllianceBernstein increased its Immunovant (IMVT) stake by 29% in Q2 2026, buying an estimated $806K and bringing the position to 116,860 shares worth $2.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1835.

AllianceBernstein first reported a position in IMVT in Q1 2020 and has held it in 26 quarters since. The position peaked at $6.17M in Q3 2020. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • AllianceBernstein held 116,860 shares of Immunovant worth $2.9M as of Q2 2026.
  • AllianceBernstein bought 26,450 Immunovant shares in Q2 2026, an estimated $806K.
  • Immunovant made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1835 holding.
  • AllianceBernstein first reported a position in Immunovant in Q1 2020 and has held it in 26 quarters since.
  • AllianceBernstein's Immunovant position peaked at $6.17M in Q3 2020.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.